Compare · ACN vs OPRX
ACN vs OPRX
Side-by-side comparison of Accenture plc (ACN) and OptimizeRx Corporation (OPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACN and OPRX operate in Real Estate (Real Estate), so they compete in similar markets.
- ACN is the larger of the two at $95.83B, about 763.4x OPRX ($125.5M).
- ACN has been more active in the news (15 items in the past 4 weeks vs 1 for OPRX).
- ACN has more recent analyst coverage (25 ratings vs 11 for OPRX).
- Company
- Accenture plc
- OptimizeRx Corporation
- Price
- $143.51-0.76%
- $6.71+0.75%
- Market cap
- $95.83B
- $125.5M
- 1M return
- -13.37%
- -
- 1Y return
- -49.25%
- -
- Industry
- Real Estate
- Real Estate
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 15
- 1
- Recent ratings
- 25
- 11
Accenture plc
Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company also provides outsourcing services. It serves communications, media, high tech, software, and platform companies; banking, capital market, and insurance industries; and consumer goods, retail, travel services, industrial, and life science industries, as well as clients in health, public service, chemicals and natural resources, energy, and utility sectors. Accenture plc has alliance relationships with Adobe, Alibaba, Amazon Web Services, Blue Yonder, Cisco, Dell, Google, HPE, IBM RedHat, Microsoft, Oracle, Pegasystems, Salesforce, SAP, ServiceNow, VMWare, Workday, Massachusetts Institute of Technology, Institut Polytechnique de Paris, CNH Industrial, and Reactive Technologies. It has an agreement with Duke Energy Corporation for the development of a technology platform designed to measure actual baseline methane emissions from natural gas distribution systems. The company was incorporated in 2009 and is based in Dublin, Ireland.
OptimizeRx Corporation
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.
Latest ACN
- SEC Form 8-K filed by Accenture plc
- SEC Form FWP filed by Accenture plc
- NATO Announces Major Contract with Accenture to Help Advance Towards a More Agile and Resilient Digital Infrastructure
- Accenture Edge and Google Cloud Bring Scalable Agentic AI Solutions to Mid-Market Companies
- General Counsel/Corp Secretary Unruch Joel was granted 202 units of Class A ordinary shares, increasing direct ownership by 0.72% to 28,233 units (SEC Form 4)
- Chair and CEO Sweet Julie Spellman was granted 285 units of Class A ordinary shares, increasing direct ownership by 2% to 16,520 units (SEC Form 4)
- Chief Operating Officer Hogan Catherine Kiernan was granted 157 units of Class A ordinary shares, increasing direct ownership by 1% to 13,478 units (SEC Form 4)
- Chief Accounting Officer Burgum Melissa A was granted 147 units of Class A ordinary shares, increasing direct ownership by 2% to 8,726 units (SEC Form 4)
- Chief Leadership & HR Officer Clifford Katherine Lee was granted 128 units of Class A ordinary shares, increasing direct ownership by 2% to 6,659 units (SEC Form 4)
- Chief Strategy & Services Ofcr Sharma Manish was granted 135 units of Class A ordinary shares, increasing direct ownership by 2% to 5,680 units (SEC Form 4)
Latest OPRX
- OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
- OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
- OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Klema Cathy was granted 34,517 shares, increasing direct ownership by 160% to 56,137 units (SEC Form 4)
- Director Lang James Paul was granted 34,517 shares, increasing direct ownership by 9% to 433,837 units (SEC Form 4)
- Director Presti Mariyamma Varghese was granted 17,258 shares, increasing direct ownership by 132% to 30,318 units (SEC Form 4)
- Director Spangler Patrick D was granted 34,517 shares, increasing direct ownership by 78% to 78,732 units (SEC Form 4)
- Director Vos Ellen O'Connor was granted 34,517 shares, increasing direct ownership by 48% to 107,159 units (SEC Form 4)
- Director Wasson Gregory D was granted 34,517 shares, increasing direct ownership by 60% to 91,700 units (SEC Form 4)
- Director Presti Mariyamma Varghese was granted 13,060 shares (SEC Form 4)